MO6 - LIPID MANAGEMENT AND CARDIOVASCULAR RISK REDUCTION STRATEGIES - ABSTRACT PRESENTATIONS

Chair(s)

• 

  Léa Berbach, PhD(c)

  PhD student
  Centre Hospitalier de L'Université de Montréal (CHUM)
  Université de Montréal

Presenting Author(s)

• 

  Andrea de Haan

  Graduate Student
  University of Manitoba
• LQ

  Litong Qi, PhD

  Associate chief physician
  Peking University First Hospital
• 

  Michael Szarek, PhD

  Research Professor
  University of Colorado School of Medicine
• XW

  Xiaoying Wu, BSc (she/her/hers)

  PhD Candidate
  University of Alberta

This session includes four abstracts exploring lipid-lowering therapies and risk reduction approaches. Presentations address pooled analyses of tafolecimab and icosapent ethyl, early discharge strategies for low-risk ACS patients, and increased atherosclerotic risk in women with PCOS, all emphasizing prevention and personalized cardiovascular care.

Presentations:

Andrea De Haan – Reduced Emergency Visits and Safe Early Discharge for Low-Risk Acute Coronary Syndrome (ACS): Interim Results from ACS-24

Litong Qi – The Effect of Tafolecimab on Low-Density Lipoprotein Cholesterol and Lipoprotein(a): A Pooled Analysis of Phase 3 Studies

Michael Szarek – Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT

Xiaoying Wu – Progression of Atherosclerotic Cardiovascular Disease Is Increased in Those with Polycystic Ovary Syndrome: Heart Health Study in Young Women